Hanzhi Dong

发表

Valproic Acid Inhibits Peripheral T Cell Lymphoma Cells Behaviors via Restraining PI3K/AKT Pathway

J. Xiong, Zhiqiang Peng, Hanzhi Dong, 2022, Evidence-based complementary and alternative medicine : eCAM.

Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma

Qi Zhang, Wenfeng Zhang, N. Cheng, 2022, Journal of Cancer Research and Clinical Oncology.

YB-1 Expression Is Associated with Lymph Node Metastasis and Drug Resistance to Adriamycin in Breast Cancer

Wenfeng Zhang, Tenghua Yu, Hanzhi Dong, 2023, Disease markers.

Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review

Xiaofang Zhang, Qingfeng Luo, Qiu-ming He, 2021, Frontiers in Oncology.

Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study

Li Liu, L. Xiao, Lin Zeng, 2023, Cancer Immunology, Immunotherapy.

Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study

Yan Li, Li Liu, Li Liu, 2023, Discover Oncology.

Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

Jie Peng, Li Liu, L. Xiao, 2022, Digestive Diseases.

Nucleolar stress promotes and cooperates with ferroptosis to suppress cancer growth

J. Xiong, Jun Deng, B. Xie, 2023, Science China Life Sciences.

Advances in immune regulation of the G protein-coupled estrogen receptor.

Xiaoqian Zeng, Hanzhi Dong, Zhiqiang Peng, 2024, International immunopharmacology.

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Yuan Cao, Hanzhi Dong, Zhe Sun, 2023, BMC Cancer.